Ahlström, F.H.G. http://orcid.org/0000-0002-4120-8647
Mätlik, K.
Viisanen, H.
Blomqvist, K.J.
Liu, X.
Lilius, T.O.
Sidorova, Y.
Kalso, E.A.
Rauhala, P.V.
Funding for this research was provided by:
Seventh Framework Programme (FP7/2007–2013)
Finska Läkaresällskapet
H2020 Marie Skłodowska-Curie Actions (798944)
Article History
Received: 21 August 2020
Accepted: 6 June 2021
First Online: 30 July 2021
Declarations
:
: The 3Rs principle was applied and ARRIVE guidelines were followed during the study [CitationRef removed, CitationRef removed]. All procedures were approved by the Regional State Administrative Agency for Southern Finland (ESAVI-9697/04.10.07-2017). The law on the Protection of Animals Used for Scientific or Educational Purposes (497/2013) and Directive 2010/63/EU on the protection of animals used for scientific purposes Text with EEA relevance were followed fully.
: Not applicable.
: Not applicable.
: Not applicable.
: Eija Kalso has received consultant honoraria from Orion Pharma and Pfizer. The consultancy is indirectly related to the submitted work. The authors have no other conflicts of interest to declare that are relevant to the content of this article.